{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:42:34Z","timestamp":1789666954350,"version":"4.0.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:p>Evans syndrome is defined by bilineal autoimmune cytopenia, typically coombs positive hemolytic anemia and thrombocytopenia. Corticosteroids are the mainstay of treatment, with rituximab and\/or mycophenolate mofetil often used in steroid-refractory cases. However, no treatment methodology has ever evaluated by a randomized clinical trial. We present a 15-year-old boy with Evans syndrome and common variable immunodeficiency who experienced a severe, refractory flare 16 months postsplenectomy. After failing to respond to multiple other agents, he achieved a durable response to a bortezomib-based regimen. Bortezomib may be a reasonable second or third line option, especially before high-morbidity therapies such as splenectomy or stem cell transplantation.<\/jats:p>","DOI":"10.1097\/mph.0000000000001325","type":"journal-article","created":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T20:06:20Z","timestamp":1538769980000},"page":"e110-e113","source":"Crossref","is-referenced-by-count":12,"title":["Successful Treatment of an Adolescent Male With Severe Refractory Evans Syndrome Using Bortezomib-based Therapy"],"prefix":"10.1097","volume":"42","author":[{"given":"Tristan","family":"Knight","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology and Oncology, Children\u2019s Hospital of Michigan"},{"name":"Wayne State University School of Medicine, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaddanapudi","family":"Ravindranath","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology and Oncology, Children\u2019s Hospital of Michigan"},{"name":"Wayne State University School of Medicine, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael U.","family":"Callaghan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology and Oncology, Children\u2019s Hospital of Michigan"},{"name":"Wayne State University School of Medicine, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bjh.13866","article-title":"How I manage Evans syndrome and AIHA cases in children","volume":"172","author":"Miano","year":"2016","journal-title":"Br J Haematol"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"e27260","DOI":"10.1002\/pbc.27260","article-title":"Diagnosis and management of chronic and refractory immune cytopenias in children, adolescents, and young adults","volume":"65","author":"Rotz","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0308-2261(21)00630-5","article-title":"Immune haemolytic disease: the autoimmune haemolytic anaemias","volume":"4","author":"Pirofsky","year":"1975","journal-title":"Clin Haematol"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0022-3476(80)80258-7","article-title":"Evans syndrome in childhood","volume":"97","author":"Pui","year":"1980","journal-title":"J Pediatr"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJM195101252440401","article-title":"The treatment of acquired hemolytic anemia with adrenocorticotrophic hormone (ACTH)","volume":"244","author":"Dameshek","year":"1950","journal-title":"N Engl J Med"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJM198501313120519","article-title":"High-dose methylprednisolone in acute immune cold hemolysis","volume":"312","author":"Meytes","year":"1985","journal-title":"N Engl J Med"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fped.2015.00079","article-title":"Evans syndrome in children: long-term outcome in a prospective french national observational cohort","volume":"3","author":"Aladjidi","year":"2015","journal-title":"Front Pediatr"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3324\/haematol.11540","article-title":"Rituximab therapy for childhood Evans syndrome","volume":"92","author":"Bader-Meunier","year":"2007","journal-title":"Haematologica"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.1097\/MPH.0b013e3181e40f45","article-title":"Successful treatment of mycophenolate mofetil in a child with refractory Evans syndrome","volume":"32","author":"Guirat-Dhouib","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bjh.13010","article-title":"Sirolimus for the treatment of multi-resistant autoimmune haemolytic anaemia in children","volume":"167","author":"Miano","year":"2014","journal-title":"Br J Haematol"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1046\/j.1442-200x.1999.01004.x","article-title":"Treatment of refractory Evans\u2019 syndrome with cyclosporine and prednisone","volume":"41","author":"U\u00e7ar","year":"1999","journal-title":"Pediatr Int"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00043426-199905000-00016","article-title":"Evans syndrome: successful management with multi-agent treatment including intermediate-dose intravenous cyclophosphamide","volume":"21","author":"Gombakis","year":"1999","journal-title":"J Pediatr Hematol Oncol"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ajh.2830440404","article-title":"Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients","volume":"44","author":"Flores","year":"1993","journal-title":"Am J Hematol"},{"issue":"suppl","key":"R14-20230918","first-page":"ECR13","article-title":"Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab","volume":"91","author":"Cheung","year":"2006","journal-title":"Haematologica"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood-2014-06-583260","article-title":"Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment","volume":"124","author":"Seidel","year":"2014","journal-title":"Blood"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2549.x","article-title":"Successful unrelated cord blood transplantation in a 7-year-old boy with Evans syndrome refractory to immunosuppression and double autologous stem cell transplantation","volume":"76","author":"Urban","year":"2006","journal-title":"Eur J Haematol"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.bbmt.2014.06.032","article-title":"Bortezomib for refractory autoimmunity in pediatrics","volume":"20","author":"Khandelwal","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/bloodadvances.2016001412","article-title":"Bortezomib-based antibody depletion for refractory autoimmune hematological diseases","volume":"1","author":"Ratnasingam","year":"2016","journal-title":"Blood Adv"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/17474086.2016.1216311","article-title":"The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders","volume":"9","author":"Citrin","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2009-09-242917","article-title":"Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib","volume":"115","author":"Carson","year":"2010","journal-title":"Blood"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fimmu.2014.00137","article-title":"Immunophenotype of Normal and Myelomatous Plasma-Cell Subsets","volume":"5","author":"Robillard","year":"2014","journal-title":"Front Immunol"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.1182\/blood.V128.22.4819.4819","article-title":"Daratumumab Is Effective in the Treatment of Refractory Post-Transplant Autoimmune Hemolytic Anemia: A Pediatric Case Report","volume":"218","author":"Tolbert","year":"2016","journal-title":"Blood"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:27:25Z","timestamp":1695011245000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001325","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}